In vivo thymulin treatments enhance avian lung natural killer cell cytotoxicity in response to infectious bronchitis virus.
Previous work has shown that in vitro thymulin treatments have the ability to enhance natural killer (NK) cell cytotoxicity. The purpose of the experiments presented here was to examine the in vivo effects of thymulin on avian NK cell activity in response to a viral infection. Five and a half-week-old K-strain chickens infected with avian infectious bronchitis virus (IBV) served as the model for these experiments. Daily thymulin injections began at varying time points prior to or post-infection. The controls received daily injections of the ZnCl(2)-containing carboxymethyl-cellulose (CMC) diluent. A 51Cr-cytolytic release assay was used to determine the activity of the NK cells harvested via lung lavage from the respiratory tracts of infected chickens. The results of these experiments showed that in vivo thymulin treatments enhance NK cytotoxicity. The greatest enhancement of NK cytotoxicity was observed at 10 days post-infection in those chickens that began receiving thymulin after infection. These results suggest that thymulin may not only have a role in enhancing immunosurveillance but also in enhancing the response of the innate immune system following infection. Dose-response experiments found that the 50 ng/100 g body weight (Bwt) dose significantly depressed the cytolytic activity of the NK cells in comparison to either the 10 ng/100 g Bwt dose or the control.
Oliver
Molly A
MA
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, C5-103 VMC, Ithaca, NY 14853, USA.
Marsh
James A
JA
D000818:Animals; D002645:Chickens / Q000276:immunology / Q000821:virology; D018352:Coronavirus Infections / Q000188:drug therapy / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D001351:Infectious bronchitis virus / Q000276:immunology*; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology*; D008168:Lung / Q000187:drug effects* / Q000276:immunology* / Q000821:virology; D008297:Male; D013935:Thymic Factor, Circulating / Q000008:administration & dosage / Q000494:pharmacology*
D013935:Thymic Factor, Circulating